Bone Shield from Douglas Laboratories is a
dietary supplement with highly absorbable calcium,
vitamin D, ipriflavone, and soy isoflavones that
provides outstanding nutritional support for bone
structure and function.
The adult human body contains approximately 1,200 g of
calcium, about 99% of which is present in the skeleton.
Bone is constantly turning over, a continuous process of
formation and resorption. In children and adolescents, the
rate of formation of bone mineral predominates over the
rate of resorption. Once one reaches peak bone mass,
sometime between the age of 20 and 30, bone formation
slows down and bone resorption begins to prevail over
bone formation, beginning the cycle of progressive, ageassociated
bone demineralization. Therefore, in normal
aging, there is a gradual loss of bone.
The condition of reduced bone mineral density can
increase risk of fractures and affects a large proportion of
the elderly in developed countries. Caucasian and Asian
women typically have low peak bone densities, and
therefore, are at the greatest risk of fractures in later life. It
is generally accepted that obtaining enough dietary calcium
throughout life can significantly decrease the risk of
fractures due to reduced bone density. Among other
factors, such as regular exercise, gender and race, calcium
supplementation during childhood and adolescence
appears to be a prerequisite for maintaining adequate bone
density later in life. But even the elderly can benefit
significantly from supplementation with dietary calcium.
In women, bone loss is generally accelerated following
menopause. The decline in estrogen levels associated with
menopause appears to put women at increased risk for
declining bone density and associated fractures. Ipriflavone,
derived from naturally occurring isoflavones, promotes bone
density by inhibiting bone resorption. Numerous studies of
postmenopausal women and individuals whose bones are
showing signs of demineralization have investigated the
benefits of ipriflavone on bone health. Laboratory and
clinical studies have documented ipriflavone’s positive effect on bone density.
Experts agree that ipriflavone appears to directly inhibit
osteoclast activity, thereby decreasing bone resorption.
Osteoclasts and osteoblasts are two primary types of bone
cells. Osteoblasts, the more exterior cells, are responsible
for bone mineralization. Osteoclasts, found beneath the
osteoblasts, are responsible for bone resorption. When
calcium levels in the blood drop, the osteoblasts change
shape, allowing the osteoclasts to become exposed and
release calcium from the bones to the rest of the body.
Scientists suspect ipriflavone may also stimulate osteoblast
activity. Since osteoblasts are responsible for laying down
new bone, an increase in osteoblast activity would result in
increased bone mineralization. This suggests ipriflavone
may not only inhibit the breakdown of existing bone, but
also encourage the formation of new bone.
In addition, Bone Shield contains Novasoy?, a soy
isoflavone concentrate. Isoflavones from soy, including
genistein and daidzein are a class of phytoestrogens, plantderived
compounds that are similar in structure and/or
function to animal estrogens. Epidemiological studies
have found that individuals with high soy intakes often
enjoy certain health advantages. Numerous laboratory and
clinical studies, investigating the health benefits of soy
products, have identified soy isoflavones as key
components responsible for the health benefits associated
with soy foods. Isoflavones have both weak estrogenic and
anti-estrogenic activity, which may contribute to their
ability to moderate menopausal symptoms and support
maintenance of bone mineral density. Isoflavones also help
protect the cardiovascular system, support the immune
system, inhibit angiogenesis, and protect against oxidative
damage as antioxidants.